MAVENIR
13.9.2022 09:01:44 CEST | Business Wire | Press release
Deutsche Telekom and Mavenir announced the successful delivery and deployment of cloud-native 5G Core to Deutsche Telekom in Germany. Deutsche Telekom selected Mavenir as the supplier for software applications to run on its defined hardware and the existing Kubernetes-based platform of its German business, ensuring an open architecture approach. As part of the deployment process, the Converged Packet Core was integrated with Telekom’s existing multi-vendor access network and other system components.
The new Converged Packet Core supports data, voice, and messaging services and network slicing. The initial network slicing use case is focused on live video broadcasting. The deployment has been successfully certified against devices from the major terminal vendors.
The Mavenir solution is based on automated software delivery and network upgrades. This will allow new Converged Packet Core services with all the required network functions to be deployed in minutes by using the automation framework of Deutsche Telekom. It is largely self-updating for the entire lifecycle of each application. The platform can automatically synchronize production environment resources and configuration with changes expressed in code. It is therefore less prone to the human errors that come with manual testing and deployment.
Dr. Abdurazak Mudesir, Group CTO Deutsche Telekom, said: “The deployment of a cloud-native Standalone (SA) core marks a key milestone in the evolution of our 5G architecture. This sets us on a path towards a fully automated network with the reliability, massive scale and flexibility required to deliver innovative 5G SA services to our consumer and enterprise customers.”
Pardeep Kohli, Mavenir’s President and CEO, said, “The Mavenir solution deployed with Deutsche Telekom in Germany, creates the foundation for the future introduction of 5G standalone enabling new applications and services to take advantage of 5G features such as low latency and network slicing.”
Key attributes of Mavenir’s solution include:
- Open Architecture: uses Telekom-defined hardware, a Kubernetes-based platform, and the automation framework of Deutsche Telekom.
- Network slicing support: with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design: a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Telekom’s Containers-as-a-Service (CaaS) that can be run on any public, private or hybrid cloud environment.
- Third-party vendor network function (NF) integration: integrated with multiple third-party vendors, including 4G and 5G access network and subscriber management functions.
- Converged architecture: Supports 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform by Deutsche Telekom.
Mavenir’s Converged Packet Core solution is part of its cloud-native MAVcore portfolio built on an open architecture which offers easy scaling of applications and services, hardware decoupling, agility, portability and resilience.
Supporting Material:
- Case Study YouTube Video: GitOps Based Cloud Native 5GC Lifecycle Management – Based on Mavenir 5GC Implementation in Deutsche Telekom Technik with Das Schiff (T-CaaS @ TDG) Platform - Michal Sewera & Samy Nitsche, Deutsche Telekom
- White Paper: Move as Fast as You Can to the 5GC
A TCO Analysis of the Transition to a Converged 5G Core
- Solution Brief: Mavenir’s Converged Packet Core Solution
About Deutsche Telekom: https://www.telekom.com/companyprofile
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom